Physician profile
Christian E Sandrock
NPI 1013997030
$2,105,398.48
in general payments reported to CMS, 2019-2025
16 companies · $292K in 2025
The $292K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209K · 2020: $155K · 2021: $380K · 2022: $535K · 2023: $290K · 2024: $245K · 2025: $292K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $519K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $115K · Travel and Lodging: $101K · Consulting Fee: $68K · Food and Beverage: $18K · Honoraria: $6,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $519,118.90 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $115,195.00 |
| Travel and Lodging | $101,028.99 |
| Consulting Fee | $67,969.50 |
| Food and Beverage | $17,533.27 |
| Honoraria | $6,048.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575,747.84 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Janssen Research & Development, LLC | $332,275.00 | 2021-2022 | |
| Shionogi INC | $306,640.44 | 2019-2025 | Fetroja |
| Allergan, INC. | $265,792.73 | 2019-2021 | |
| Pfizer INC. | $248,053.75 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $239,995.45 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $71,924.98 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Melinta Therapeutics, LLC | $23,928.48 | 2022-2025 | Vabomere, Rezzayo, Kimyrsa |
| La Jolla Pharmaceutical Company | $20,080.12 | 2019-2025 | Xacduro, Giapreza |
| Pfizer International LLC | $10,075.00 | 2021-2024 | |
| Nabriva Therapeutics, Plc | $6,701.00 | 2022 | |
| Astellas Pharma US INC | $3,375.74 | 2019-2025 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $650.62 | 2019 | |
| Abiomed | $123.97 | 2019 | |
| Advanced Respiratory, INC | $20.24 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Sandrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.